Conclusion: RA implies a higher CV risk. Traditional CV risk factors explains only partially the global risk. These findings support that RA acts as an independent cardiovascular risk factor.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.6420

SAT0078

SAFETY OF LOW DOSE METHOTREXATE (MTX) IN HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION

A. Gunay¹, A. Davidson¹, I. Colmegna¹, D. Lacaille², H. Loewen³, M. Meltzer⁴, Y. Mengistu⁵, R. Scuccimarrì¹, Z. Yirsaw⁵, S. Bernatsky¹, C. Hitchon³. ¹McGill University, Montreal, Canada; ²Arthritis Research Canada, Richmond, Canada; ³University of Manitoba, Winnipeg, Canada; ⁴Thomas Jefferson University, Philadelphia, United States of America; ⁵Addis Ababa University, Addis Ababa, Ethiopia

Background: Increased awareness of the efficacy of MTX in rheumatic disease is leading to more MTX use in patients from HIV endemic areas. While HIV related immunosuppression may contribute to improvement of some rheumatic diseases, immune reconstitution from highly active antiretroviral therapy (HAART) may lead to exacerbation or presentation of autoimmune disorders for which MTX therapy may be warranted. Most management guidelines for rheumatic disease do not address MTX use in the context of HIV.

Objectives: To systematically review the published literature on the safety of using MTX ≤30mg per week in HIV.

Methods: We searched CINAHL, Embase, Global, MEDLINE and World of Science databases (Jan 1990 to May 2018) for terms including 'methotrexate' and 'human immunodeficiency virus'. We also searched citations from review articles. Titles, abstracts or full manuscripts were screened independently by 2 reviewers to identify studies reporting HIV in patients taking MTX. Study quality was assessed using the McGill Mixed Methods Appraisal Tool (MMAT). Data was extracted on MTX and HIV adverse events (MTX toxicity, HIV viral load, CD4 count). Descriptive summaries are presented for studies providing outcomes in patients taking MTX ≤30mg per week.

Results: After removing duplicates and studies not meeting criteria or not providing sufficient information, 42 of the 2714 identified reports were included (1 clinical trial, 2 cohort, 1 cross-sectional study, 38 case reports/case series). Most reports (81%) originated from USA or Europe. Study quality was generally good with most studies fulfilling 50-100% of MMAT criteria. The randomized controlled trial (USA) assessing MTX on atherosclerotic disease in HIV showed that adverse events were more common in MTX versus placebo (12.8% vs 5.6%, p non-inferiority <0.05) and included infection, transient CD4 and CD8 drop, pulmonary toxicity, and death (1 attributed to MTX/HIV, 1 unrelated). One cohort study (South Africa) reported 43 RA patients on MTX who acquired HIV. In this cohort, RA generally improved despite only 5 individuals continuing MTX. No data on MTX adverse event rates was reported. One cohort study (USA) reported 13 HIV patients with myositis. One received MTX (with other immunosuppression) without MTX adverse effects but died due to AIDS. A cross-sectional study (France) of 43 HIV pts with autoimmune disease reported one patient on MTX (and other immunosuppression) developed an adverse event (cytopenia) compared to 5/33 patients not on MTX (cytopenia). The 38 case reports/series described 54 individuals with HIV receiving MTX. Of these studies, 27 (describing 42 subjects) reported on MTX adverse events and 35 (describing 46 subjects) reported on HIV adverse events. MTX adverse events developed in 29 subjects (hematologic 13, renal/hepatic 1, opportunistic infections 10, other events 2). HIV adverse events were noted in 23 subjects (Kaposi's sarcoma 4, CD4 decrease 16, HIV viral titer increase 4). Five deaths were reported (2 infection, 1 infection and wasting, 2 HIV related deaths). Most subjects also received corticosteroids or other immunosuppressants including biologics.

Conclusion: There remains limited data on the safety of low dose MTX in HIV. Surveillance for HIV is warranted for individuals on MTX who are at risk for acquiring HIV. Caution and careful monitoring for MTX toxicity, opportunistic infections and HIV state is suggested if MTX is used in the setting of HIV particularly if combined with other immunosuppression.

References:

- [1] Clin Infectious Disease 2019:68
- [2] J Rheumatology 2014:41
- [3] Arthritis and Rheumatism 2003:49
- [4] Medicine 2017:96

Acknowledgments : Funding from International League Against Rheumatism McGill University Global Health Scholar Awards

Disclosure of Interests: Alize Gunay: None declared, Anna Davidson: None declared, Ines Colmegna: None declared, Diane Lacaille: None declared, Hal Loewen: None declared, Michele Meltzer: None declared, Yewondwossen

Mengistu: None declared, Rosie Scuccimarrì: None declared, Zenebe Yirsaw: None declared, Sasha Bernatsky: None declared, Carol Hitchon Grant/research support from: UCB Canada; Pfizer Canada

DOI: 10.1136/annrheumdis-2020-eular.2968

SAT0079

FEATURES OF CLINICAL MANIFESTATIONS IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS IN THE PRESENCE OF SIGNS OF CENTRAL SENSITIZATION

A. Karateev¹, E. Filatova¹, E. Pogozheva¹, V. Amirdzhanova², E. Nasonov², A. Lila¹. ¹Nasonova Research Institute of Rheumatology, Moscow, Russian Federation; ²Nasonova Research Institute of Rheumatology, Moscow, Russian Federation

Background: The presence of central sensitization (CS) is observed in 25-30% of patients with rheumatoid arthritis (RA). CS is associated with more severe pain, depression, and anxiety.

Objectives: To evaluate the effect of CS on activity indicators and clinical manifestations in patients with active RA.

Methods: The study group consisted of 60 patients with medium or high RA activity (DAS28 ≥3.2), 75% female, age 54.5±17.8 years, 82.1% RF "+", 75% ACPA "+", DN4 and PainDETECT questionnaires were used to identify CS signs. Signs of CS were detected in 43% of patients. Clinical parameters and indicators of disease activity in patients with RA CS "+" and CS "-" were compared.

Results: Groups of patients with RA CS "+" and CS "-" did not differ in age - 55.5 [48.0; 67.5] and 54.0 [40.0; 62.0], $p=0.26$, body mass index - 24.54 [22.6; 26.78] and 25.04 [21.34; 29.665] kg/m², $p=0.64$, duration of illness: 6.5 [2.5; 13.0] and 10.0 [5.0; 16.5] years, $p=0.13$, level of C-reactive protein: 7.2 [1.0; 23.4] and 8.1 [3.6; 24.3], $p=0.53$.

SC "+" patients had a higher level of pain on a visual analog scale, VAS (patient score) - 70.0 [60.0; 80.0] and 60.0 [40.0; 70.0], $P=0.01$; DAS28 - 5.33 [3.38; 6.42] and 4.5 [3.645; 5.4], $p=0.04$; EQ-5D - 0.52 [0.02; 0.52] and 0.59 [0.52; 0.71], $p=0.01$; anxiety level (Hads-T) - 8.0 [7.0; 10.0] and 4.5 [2.5; 6.0], $p=0.001$ and depression (Hads-D) - 7.5 [6.0; 10.5] and 5.0 [2.5; 7.5], $p=0.02$. The groups did not differ significantly in the values of SDAI, CDAI, and HAQ, as well as in the assessment of health by the doctor (VAS) - 60.0 [50.0; 70.0] and 60.0 [50.0; 60.0], $p=0.42$.

Conclusion: The presence of SC is associated with more intense pain, anxiety, depression, and DAS28 activity. This should be taken into account when planning therapy, including deciding whether to "switch" DMARDs and prescribing antidepressants and anticonvulsants.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.3954

SAT0080

COMPARATIVE ANALYSIS OF FRAGILITY FRACTURE IN PATIENTS WITH ELDERLY ONSET RHEUMATOID ARTHRITIS AND YOUNG ONSET RHEUMATOID ARTHRITIS

P. Kozhevnikova¹, I. Dydykina¹, P. Kovalenko¹, A. Lila¹. ¹V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation

Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease, characterized by erosive arthritis and systemic organ involvement. Chronic inflammation, long RA disease duration, decreased physical activity, immobilization, glucocorticoids use lead to local (periarticular osteoporosis) and generalized loss of bone tissue, decrease in bone mineral density, contravention of microarchitectonics and increased risk of fragility (low-energy) fractures. The structure and density of bone tissue at elderly onset RA, in addition to the above factors, are affected by comorbid diseases, sex steroids level decrease and molecular changes in bone tissue, specifically attributed to aging, followed by increased bone resorption. Fractures reduce the quality of life, have a negative impact on the course of the underlying and concomitant diseases.

Objectives: Compare frequency of fragility fracture in patients with elderly onset rheumatoid arthritis and young onset rheumatoid arthritis.

Methods: We included 474 patients with RA diagnosed at 25–78 years old and fulfilled the American College of Rheumatology (formerly American Rheumatism Association) classification criteria for RA revised in 1987. The patients were divided into two groups depending on age at the RA-onset: The first group (group I) included 217 patients with young onset RA (at 25 to 44 years), second group (group II) included 66 patients with elderly onset RA (aged ≥60 years). The distribution of patients into groups was consistent with the age classification of the World Health Organization. In total, it was selected 283 RA patients. The mean age in group I was 50.4 years, in group II - 71.2 years. The mean age at the onset